On 12 Nov 2026 Thermo Fisher Scientific closed at $699.44, +21.0% this year; market cap $259.49bn, P/E 36.6.
Health Care · Life Sciences Tools & Services · NYSE · United States
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
| Market cap | $259.49bn |
| P/E (trailing) | 36.6 |
| EPS (TTM) | $19.09 |
| Beta | 0.84 |
| Dividend | $1.88 |
| Dividend yield | 0.27% |
| Ex-dividend date | 15 Dec 2026 |
| Latest report | 21 Oct 2026 |
| Next earnings | 20 Jan 2027 |
| YTD | +21.0% |
| 1Y | +19.4% |
| 3Y | +16.6% |
| 5Y | +2.2% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $44.56bn | $6.74bn | $6.29bn |
| 2024 | $42.88bn | $6.33bn | $7.27bn |
| 2023 | $42.86bn | $6.00bn | $6.93bn |
| 2022 | $44.91bn | $6.95bn | $6.91bn |
| 2021 | $39.21bn | $7.72bn | $7.02bn |
Base value $515.88 (-26.2% vs price); 0 of 1 methods above the price. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.